Early benefit assessment: Detailed analysis of all G-BA resolutions

The AMNOG monitor provides current, well-founded analyses of all early benefit assessments and an overview of the negotiated reimbursement prices in Germany. It is an indispensable tool for HTA, market access and pricing managers.
 

List of all G-BA Resolutions

The AMNOG monitor includes detailed analyses of every sinlge benefit assessment since 2011. more >>

Interactive Analysis

Our comprehensive online analysis tool helps answer your individual questions. more >>

Intelligent search

Search for answers in all G-BA resolutions, justifications, IQWiG assessments and much more >>

"Interactive analysis" step by step

A quick tour through the AMNOG Monitor's powerful analysis tool. more >>

"Detailed analysis" step by step

A tour through the structure of our quantitative and qualitative analyses of each G-BA resolution. more >>

Gain a better insight

Identify decision-paths and trends in early benefit assessment. The AMNOG monitor is indispensable for managers and decision-makers in market access, pricing and reimbursement.

Dear AMNOG Monitor readers,

Last month, the German Health Minister Karl Lauterbach presented four more draft laws. They will have no direct influence on early benefit assessments, however:

  • Reform of emergency care
  • Health Digital Agency Act
  • Living organ donation reform
  • Act to strengthen public health.

A further 15 laws have been announced for this legislative period. It is to be hoped that the plethora of laws will be so well drafted and harmonised that they will actually improve patient care and not just create additional structures and costs. www.bundesgesundheitsministerium.de

In August, there were 13 new G-BA resolutions on early benefit assessments, the results of which are shown in the table below. Seven new procedures were started. For our international customers, the individual analyses of the resolutions are now also available in English throughout - including retrospectively for all proceedings that have already been completed.

We are frequently asked whether data and analyses from the AMNOG Monitor may be used for publications. We are pleased if the AMNOG Monitor can support you in the preparation of scholarly works, and we only ask you to provide us with a specimen copy or a PDF file of your publication. The citation follows the guidelines of the respective journal, for example a current citation of the AMNOG Monitor from August 2024: www.nature.com/articles/s41599-024-03374-x 

Thank you for the many suggestions and interesting discussions during the training sessions. We are looking forward to continue working with you.

New reimbursement prices of AMNOG products are available here.
EMA Positive Opinions for new drugs are shown here.

Kind regards,
Dr Johannes Hankowitz and Christian Rieke